Global Diabetes & Obesity Drugs Market to Show Further Growth, Claims GBI Research in Its Report Available at MarketPublishers.com12 Sep 2016 • by Natalie Aster
LONDON – A chronic metabolic disease, diabetes is characterised by hyperglycemia. Chronic hyperglycemia in diabetic patients is associated with dysfunction, failure and long-term damage of multiple organs, such as kidneys, eyes nerves, etc.
At present, there is a considerable increase in the prevalence of type 2 diabetes mellitus (T2DM). And this increase is closely linked with the ongoing rise in obesity which is already considered to be a global epidemic.
A size of the market for the diabetes and the obesity disease cluster is set to demonstrate considerable growth in the years to come. This growth will stem from success in T2DM pipeline products and rapid expansion of the worldwide patient population. An activity of the obesity pipeline is forecast to stay markedly low, though the patient population has epidemic proportions.
Cutting-edge research report “Global Diabetes and Obesity Drugs Market to 2022” drawn up by GBI Research offers a comprehensive guide to the global market for diabetes and obesity drugs. The study contains a detailed discussion of symptoms, covers etiology and pathophysiology. It investigates epidemiology patterns and contains forecasts across 7 major markets.
The report concentrates on key marketed products like Levemir, Humalog, Saxenda, Xenical, Belvoq, and more. The research study assesses the pipeline, as well. It casts light on the pipeline development landscape and unveils molecular targets in the pipeline.
The research report focuses on clinical trials and limelights generic penetration. The study discloses the overall market size and forecasts revenue on the basis of molecular targets. It pays close attention to the most prominent companies and contains strategic consolidations. The report also comprises forecasts for this market through 2022.
More in-demand research studies by our partner are available at GBI Research page.